Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04848272
PHASE1

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Sponsor: St Vincent's Institute of Medical Research

View on ClinicalTrials.gov

Summary

Phase 1 study investigating safety of lanadelumab administration to patients with lung injury

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2021-08-09

Completion Date

2024-12

Last Updated

2024-04-17

Healthy Volunteers

No

Conditions

Interventions

DRUG

Lanadelumab

Monoclonal antibody that targets active plasma kallikrein

OTHER

Saline control

Saline control

Locations (1)

St Vincent's Hospital Melbourne

Melbourne, Victoria, Australia